Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Liver Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × carotuximab × Clear all
NCT01090765 2018-05-22

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 17 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡